Quantcast

Industry news that matters to you.  Learn more

Archives for January 2012

Bruker and SISCAPA Assay Technologies Announce Joint Publication on SISCAPA-MALDI-TOF Mass Spectrometry for Biomarker Validation and Clinical Research

Bruker Corporation and SISCAPA Assay Technologies, Inc. (SAT) today announced the publication of a study in the Journal of Proteome Research demonstrating that SISCAPA MALDI-TOF mass spectrometry provides excellent precision for quantitation of proteins of interest, such as high value protein biomarkers. The publication results from an ongoing collaboration between Bruker and SAT to develop MALDI-TOF as a high precision and high throughput mass spectrometric detection method for SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) assays.

Selventa Receives Patent for Method to Identify Biomarker Profiles

Selventa, a biomarker discovery company that enables personalized healthcare through the stratification of patients based on disease-driving mechanisms, recently announced a US patent that relates methods and techniques that facilitate discovery of biomarkers, thus aiding in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases.

NextGen Sciences Launches its 82 Protein Cerebrospinal Fluid (CSF) CNS Disease Biomarker Assay

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched an expanded cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery82, for central nervous system (CNS) biomarker discovery and qualification. The new assay simultaneously measures 82 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer’s, Parkinson’s, multiple sclerosis and ALS diseases. The launch of csfdiscovery82 demonstrates the acceleration in NextGen Sciences strategy of becoming a leading player in the growing CNS biomarker market.

Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care

Precision Therapeutics, Inc. has recently expanded their BioSpeciFx product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision’s approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test.

OPKO Health Acquires Next Generation Prostate Cancer Tests

OPKO Health, Inc. yesterday announced the acquisition of an exclusive license from Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%. These novel biomarkers were developed by investigators at the University of Malmo, Sweden, University of Turku, Finland, and Memorial Sloan Kettering Cancer Center, New York. The research results indicate that these markers can predict initial biopsy results in men suspected of having prostate cancer; they have been tested in over 8,000 men and were independently validated in the European Randomized Study of Prostate Cancer Screening (Rotterdam).